GB202216961D0 - 5-meo-mt formulations - Google Patents
5-meo-mt formulationsInfo
- Publication number
- GB202216961D0 GB202216961D0 GBGB2216961.9A GB202216961A GB202216961D0 GB 202216961 D0 GB202216961 D0 GB 202216961D0 GB 202216961 A GB202216961 A GB 202216961A GB 202216961 D0 GB202216961 D0 GB 202216961D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- meo
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2216961.9A GB202216961D0 (en) | 2022-11-14 | 2022-11-14 | 5-meo-mt formulations |
| EP23813030.6A EP4618946A1 (en) | 2022-11-14 | 2023-11-14 | Formulations of 5-meo-dmt |
| PCT/GB2023/052977 WO2024105379A1 (en) | 2022-11-14 | 2023-11-14 | Formulations of 5-meo-dmt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2216961.9A GB202216961D0 (en) | 2022-11-14 | 2022-11-14 | 5-meo-mt formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202216961D0 true GB202216961D0 (en) | 2022-12-28 |
Family
ID=84840134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2216961.9A Ceased GB202216961D0 (en) | 2022-11-14 | 2022-11-14 | 5-meo-mt formulations |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB202216961D0 (en) |
-
2022
- 2022-11-14 GB GBGB2216961.9A patent/GB202216961D0/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202117828D0 (en) | New formulations | |
| IL290356A (en) | Larazotide formulations | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| IL284691A (en) | Formulations | |
| GB202204171D0 (en) | Novel formulations | |
| IL319149A (en) | Upadacitinib formulation | |
| GB202018889D0 (en) | Formulations | |
| GB202009684D0 (en) | Formulations | |
| GB202009685D0 (en) | Formulations | |
| IL321617A (en) | Bezuclastinib formulations | |
| GB202315863D0 (en) | Formulations | |
| GB202307059D0 (en) | Formulations | |
| GB202216961D0 (en) | 5-meo-mt formulations | |
| GB202115127D0 (en) | Formulations | |
| GB202115121D0 (en) | Formulations | |
| GB202103762D0 (en) | Formulations | |
| GB202103780D0 (en) | Formulations | |
| GB202103785D0 (en) | Formulations | |
| GB202018250D0 (en) | Formulations | |
| GB202018251D0 (en) | Formulations | |
| GB202108259D0 (en) | Novel formulations | |
| GB202004814D0 (en) | Novel formulations | |
| GB202004811D0 (en) | Novel Formulations | |
| GB202417829D0 (en) | Formulations | |
| IL323027A (en) | Formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |